

January 31, 2019



Sapience Therapeutics to Present at 2019 BIO CEO & Investor Conference

HARRISON, N.Y., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it is scheduled to present and conduct one-on-one meetings at 2019 BIO CEO & Investor Conference to be held in New York, NY on February 11th-12th.

Barry Kappel, Ph.D., MBA, President and Chief Executive Officer of Sapience Therapeutics, is scheduled to present on Tuesday, February 12th at 1:15 pm EST.

About Sapience Therapeutics

Sapience Therapeutics, Inc., is a privately held, preclinical biotechnology company focused on discovering and developing peptide-based therapeutics for major unmet medical needs, particularly high mortality cancers. With platform-based discovery of peptide therapeutics that disrupt protein:protein interactions, Sapience's molecules hold potential to target intracellular interactions that are traditionally considered "undruggable targets". Its lead compound, ST101, is a first-in-class molecule with potential applications in various solid tumors and hematologic malignancies. In 2016, Sapience Therapeutics closed its Series A financing, which was led by Eshelman Ventures and included investments from Celgene Corporation, TaiAn Technologies Corporation and Healthlink Capital. For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties. These statements are based on management's current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Sapience's product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. These are forward-looking statements, which speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

Contacts

Sapience Therapeutics, Inc.:
Barry Kappel

President and Chief Executive Officer
info@sapiencetherapeutics.com

Investors:

Stephanie Carrington

ICR

Stephanie.carrington@icrinc.com

(646) 277-1282



Source: Sapience Therapeutics, Inc.